Sirukumab

Sirukumab (INN, USAN) (developmental code name CNTO-136) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.[1] It acts against the proinflammatory cytokine Interleukin 6 (IL-6).

Sirukumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIL6
Clinical data
ATC code
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6450H9926N1690O1998S46
Molar mass144.6 kg/mol g·mol−1
 NY (what is this?)  (verify)

Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor[2]

Clinical trials

Rheumatoid arthritis

It has started clinical trials.[3] and reported some phase II results.[2]

In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.[4] By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.[5]

Other

The drug is currently in phase II clinical trials for the treatment of depression.[6]

See also

References
  1. "Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab" (PDF). American Medical Association.
  2. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
  3. A Study of the Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy, clinicaltrials.gov
  4. Glaxo says top-line results positive in late-stage study of sirukumab in rheumatoid arthritis. Dec 2015
  5. IL-6 in RA: What Predicts Non-Progression? - High-risk patients showed most benefit with sirukumab. Jan 2017
  6. adisinsight



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.